Trevi Therapeutics, Inc. Discusses Progress and 2022 Success of Clinical Studies for Its Investigational Oral Therapy Haduvio(TM) with The Stock Day Podcast

President and CEO of the Company, Jennifer Good, joined Stock Day host Everett Jolly.